Please login to the form below

SAR302503

This page shows the latest SAR302503 news and features for those working in and with pharma, biotech and healthcare.

Jakafi cleared for bone marrow disorder by FDA

pacritinib. Sanofi was forced to discontinue development of its fedratinib (SAR302503) candidate after cases of a rare form of encephalopathy were seen in late-stage trials.

Latest news

Sanofi pulls development of blood cancer drug

The France-based pharma company said the reason to pull fedratinib – also known as SAR302503 – was due to the drug's link to an increased risk of the brain disorder
Jakavi shows long-term survival benefit in myelofibrosis

Meanwhile, Jakavi will have the market to itself for at least as a couple of years, as rival JAK inhibitors such as Sanofi's SAR302503 and Gilead Sciences' CYT387 are still
Sanofi plans to file JAK2 inhibitor after positive phase III

Sanofi has started to prepare for regulatory filings of its blood cancer treatment SAR302503 following positive results in a pivotal study. ... In the trial, patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythaemia vera
Sanofi has 65 new compounds in development, says R&D chief

Elias Zerhouni to showcase pharma company's pipeline, promises costs will be rigorously managed
Gilead expands in cancer with $510m YM BioSciences deal

Aside from Jakafi, other JAK inhibitors being developed for myelofibrosis include Sanofi's selective JAK2 inhibitor SAR302503 - phase II data for which were presented at ASH - and Cell Therapeutics Inc's

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest Intelligence

Pharma deals during November 2013

While Sanofi announced this month that it had discontinued clinical trials of fedratinib (SAR302503), an investigational JAK2 inhibitor, Baxter entered an exclusive global agreement (headline value $172m) to develop and commercialise

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Healthcare PR Senior Account Manager: Salary TBC

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Technical Manager – Developer and Commercial Excellence, Healthc...: Excellent package

Market Access Consultant - Greater Manchester: Negotiable

Associate Scientific Director: Salary TBC

Healthcare PR Director: £100, 000 – £120, 000 benefits

Systematic Review Lead- London: Negotiable

Senior Writer, Healthcare Advertising, London: Excellent package

Account Manager: Negotiable

Integrated Brand/ Digital Senior Account Director, London: Excellent package

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Healthcare Advertising Account Manager / Senior AM / AD: Salary TBC

Senior Medical Writer: Salary is DOE

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Senior Account Manager – Healthcare Advertising: Salary TBC

Account Director, Healthcare Advertising Agency: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Subscribe to our email news alerts

PMHub

Add my company

Hive

We're a healthcare communications agency that does things differently. We put patients at the heart of everything we do, while...

Latest intelligence

The gene therapy revolution: Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...